Guggenheim upgraded InflaRx to Buy from Neutral with an $8 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IFRX:
- InflaRx price target raised to $10 from $6 at H.C. Wainwright
- InflaRx upgraded to Outperform from Market Perform at LifeSci Capital
- InflaRx (NASDAQ:IFRX) Stock Spikes: Is There Further Upside?
- InflaRx up 47% after receiving EUA for Gohibic use in COVID-19 treatment
- InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients